Search - tctmd.com

Displaying 521 - 540 of 822

Sort: Relevancy | Date

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

COVID-19: TCTMD’s Daily Dispatch for May Week 3

News Daily News

COVID-19: TCTMD’s Daily Dispatch for May Week 3

May 17, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

News Conference News ACC 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

May 16, 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

May 16, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

May 16, 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

May 16, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

News Conference News ACC 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

May 15, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

News Conference News ACC 2021

‘Enormous’ QoL Improvements With Mavacamten in HCM

May 15, 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

News Daily News

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

May 14, 2021

News Industry News

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

May 13, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.